r Intravascular ATP attenuates sympathetic vasoconstriction (sympatholysis) similar to what is observed in contracting skeletal muscle of humans, and may be an important contributor to exercise hyperaemia.
Introduction
The haemodynamic adjustment to large muscle mass or high intensity exercise is the result of a complex interaction between local vasodilatatory signals that facilitate blood flow and oxygen delivery to active skeletal muscle, and sympathetic nervous system activation for the regulation of cardiac output, total peripheral resistance and mean arterial pressure (MAP) (Marshall et al. 1961; Rowell, 1997) . Within contracting skeletal muscle, sympathetic neural vasoconstriction is significantly attenuated relative to resting tissues (Remensnyder et al. 1962; Anderson & Faber, 1991; Thomas & Victor, 1998; Tschakovsky et al. 2002; Dinenno & Joyner, 2003; Wray et al. 2004 ) and ensures adequate blood flow to active muscle despite elevated sympathetic vasoconstrictor signalling (Joyner & Thomas, 2003) . The ability of contracting skeletal muscle to attenuate sympathetic vasoconstriction, referred to as functional sympatholysis (Remensnyder et al. 1962) , is graded with exercise intensity such that mild intensity muscle contractions do not interfere with sympathetic vasoconstriction, whereas graded increases in contraction intensity result in progressively greater attenuation of sympathetic vasoconstriction (Thomas et al. 1994; Tschakovsky et al. 2002; Kirby et al. 2005) . Importantly, studies indicate that functional sympatholysis occurs post-junctionally at the level of the α-adrenoceptors, indicating specific signalling mechanisms within the resistance vasculature are responsible for attenuating vasoconstriction (Thomas et al. 1994; Buckwalter et al. 1998; Dinenno & Joyner, 2003; Rosenmeier et al. 2003a; Kirby et al. 2008) .
Accumulating evidence suggests that circulating ATP released from red blood cells (among other sources) in response to the formation of deoxy-haemoglobin may contribute to exercise hyperaemia in humans (González-Alonso et al. 2002; Crecelius et al. 2015a) . Along these lines, intra-arterial infusion of ATP induces vasodilatation sufficient to elevate blood flow to levels observed during maximal exercise (González-Alonso et al. 2002; Rosenmeier et al. 2004) , can elicit sustained vasodilatation for up to 3 h without exhibiting tachyphylaxis (Shepherd et al. 2016) and the concentration of ATP in the venous effluent of contracting skeletal muscle increases progressively during incremental exercise (González-Alonso et al. 2002; Mortensen et al. 2011; Kirby et al. 2012) . In addition to direct vasodilatation, intravascular (circulating) ATP has also been shown to attenuate local sympathetic vasoconstriction (Rosenmeier et al. 2004 (Rosenmeier et al. , 2008 Kirby et al. 2008) . Importantly, Kirby et al. (2008) demonstrated that circulating ATP attenuates direct post-junctional α 1 -and α 2 -adrenergic vasoconstriction in a graded manner, similar to that observed in contracting skeletal muscle. In humans, the dual ability to induce vasodilatation and limit α-adrenergic vasoconstriction is unique to ATP, as exogenous administration of ADP, AMP (Rosenmeier et al. 2008) , adenosine (Rosenmeier et al. 2003a (Rosenmeier et al. , b, 2004 (Rosenmeier et al. , 2008 Dinenno & Joyner, 2003 Kirby et al. 2008; Crecelius et al. 2015b) , sodium nitroprusside (SNP) (nitric oxide donor) (Tschakovsky et al. 2002; Rosenmeier et al. 2003b; Hearon et al. 2016) , potassium chloride and acetylcholine (Hearon et al. 2016) to quiescent skeletal muscle all fail to independently attenuate adrenergic vasoconstriction. Thus, how intravascular ATP signals in the skeletal muscle vasculature of humans is of particular interest in the context of exercise hyperaemia and functional sympatholysis.
It is well established that intravascular ATP elicits vasodilatation by binding P 2y receptors located on the endothelium (Burnstock & Kennedy, 1986; Winter & Dora, 2007) , although until recently the downstream signalling pathways responsible for the vasodilatatory response in humans were less clear. A number of investigations have identified a variable and modest contribution of endothelial-derived nitric oxide (NO) and prostaglandins (PGs) (ß20%) in response to intra-luminal ATP infusion in humans (Rongen et al. 1994; van Ginneken et al. 2004; Mortensen et al. 2009; Crecelius et al. 2011) . More recent data from our laboratory identified activation of inwardly rectifying K + (K IR ) channels as a primary contributor to ATP-mediated vasodilatation in the human forearm . Activation of K IR channels can hyperpolarize vascular smooth muscle cells directly (Jackson, 2005) or amplify hyperpolarizing signals generated from the endothelium (Jantzi et al. 2006; Sonkusare et al. 2016) . Importantly, K IR channel activation and subsequent vascular hyperpolarization is an important component of conducted vasodilatation (Rivers et al. 2001; Jantzi et al. 2006; , which is implicated in the coordination of blood flow responses during muscle contractions (Wölfle et al. 2009 ). Indeed, our laboratory has recently demonstrated that inhibition of K IR channels attenuates the normal vasodilatatory response to handgrip exercise by ß30% (Crecelius et al. 2014) . However, despite combined blockade of K IR channels, Na + /K + -ATPase activity, NO and PG production resulting in greater than ß40% decrease in the normal vasodilatatory response to exercise, the ability of contracting skeletal muscle to attenuate α 1 -adrenergic vasoconstriction remained intact (Crecelius et al. 2015b) . Clearly the local milieu of contracting skeletal muscle is quite complex, so whether these pathways are involved in the ability of intravascular ATP to attenuate α 1 -adrenergic vasoconstriction in resting human skeletal muscle is unknown.
Accordingly, given the independent role of K IR channel activation in ATP-mediated vasodilatation, the primary purpose of this study was to determine whether the ability of ATP to blunt α 1 -adrenergic vasoconstriction is dependent upon K IR channel activity in humans. A secondary purpose was to determine the effect of inhibition of NO and PG synthesis, as well as combined inhibition along with K IR channels and Na + /K + -ATPase, on the ability of ATP to modulate α 1 -adrenergic vasoconstriction. We hypothesized that despite significant attenuation of the vasodilatatory response to ATP by inhibition of K IR channels alone or in combination with blockade of NO, PGs and Na + /K + -ATPase, intravascular ATP would maintain the ability to attenuate α 1 -adrenergic vasoconstriction in humans.
Methods

Subjects
With Institutional Review Board approval and after written informed consent, a total of 13 young healthy adults [7 men, 6 women; age = 22 ± 1 years; weight = 65.5 ± 4.5 kg; height = 170 ± 4 cm; body mass index = 22.6 ± 0.7 kg m −2 ; forearm volume (FAV) = 915 ± 79 ml; means ± SEM] participated in the present study. All subjects were sedentary to moderately active, non-smokers, non-obese, normotensive and not taking any medications. Studies were performed after an overnight fast and 24 h abstention from caffeine and exercise. Female subjects were studied during the early follicular phase of their menstrual cycle or placebo phase of oral contraceptive use to minimize any potential cardiovascular effects of sex-specific hormones. The subjects were studied in the supine position with the experimental arm abducted to 90 deg and slightly elevated above heart level upon a tilt-adjustable table. All studies were performed according to the Declaration of Helsinki.
Arterial catheterization, arterial blood pressure and heart rate A 20 gauge, 7.6 cm catheter was placed in the brachial artery of the non-dominant arm under aseptic conditions after local anaesthesia (2% lidocaine). The catheter was continuously flushed at 3 ml h −1 with heparinized saline and connected to a pressure transducer to measure MAP, and a three-port connector for local infusion of vasoactive drugs. Heart rate (HR) was determined using a three-lead electrocardiogram (Cardiocap/5, Datex-Ohmeda, Louisville, CO, USA) (Crecelius et al. , 2015b .
Forearm blood flow and vascular conductance
A 12 MHz linear-array ultrasound probe (Vivid 7, General Electric, Milwaukee, WI, USA) was used to determine brachial artery mean blood velocity (MBV) and brachial artery diameter. The probe was placed over the brachial artery proximal to the catheter insertion site as previously described Hearon et al. 2016) . For blood velocity measurements, the probe insonation angle was maintained at <60 deg and the frequency used was 5 MHz. The Doppler shift frequency spectrum was analysed via a Multigon 500M TCD (Multigon Industries, Mt Vernon, NY, USA) spectral analyser from which mean velocity was determined as a weighted mean of the spectrum of Doppler shift frequencies. Brachial artery diameter was measured in triplicate at the end of rest, during steady-state hyperaemia prior to infusion of phenylephrine (PE), and at the end of the PE vasoconstrictor response (see Experimental Protocol below; Fig. 1 ). Forearm blood flow (FBF) was calculated as: FBF = MBV × π (brachial artery diameter/2) 2 × 60, where FBF is in ml min −1 , MBV is in cm s −1 , brachial diameter is in cm, and 60 is used to convert from ml s −1 to ml min −1 . Forearm vascular conductance (FVC) was calculated as (FBF/MAP) × 100, and expressed as ml min −1 100 mmHg −1 . All studies were performed in a cool (20-22°C) temperature-controlled J Physiol 595.15 environment with a fan directed toward the forearm to minimize the contribution of skin blood flow to forearm haemodynamics.
Vasoactive drug infusion
All drug infusions occurred via a brachial artery catheter to ensure the effects of experimental drugs remained localized to the forearm vasculature. To strictly control the vasoconstrictor stimulus across all conditions, PE (selective α 1 -agonist; Sandoz Inc., Princeton, NJ, USA) was infused at 0.065 μg (dl FAV) −1 min −1 in male subjects and was doubled to 0.125 μg (dl FAV) −1 min −1 in female subjects to account for reduced adrenergic responsiveness and elicit similar magnitude of vasoconstrictor response across subjects (Kneale et al. 2000; Kirby et al. 2008) . The doses of PE were chosen based on our previous experience in eliciting robust vasoconstriction at rest and during vasodilatator infusion, and was adjusted for the steady-state hyperaemic condition as previously described (see below) (Dinenno & Joyner, 2003; Hearon et al. 2016) .
ATP (A7699; Sigma, St Louis, MO, USA) was infused at a dose of 4.6 μg (dl FAV) −1 min −1 based on previous studies from our laboratory demonstrating that this dose of ATP significantly attenuates PE-mediated vasoconstriction (Kirby et al. 2008 . Because ATP infusion elevates FBF, vasodilatatory agents were infused to match hyperaemia across conditions, and thus demonstrate that any attenuation in α 1 -adrenergic vasoconstriction during ATP infusion is not due to elevations in blood flow per se (Tschakovsky et al. 2002; Hearon et al. 2016) . In the present study, adenosine (ADO; Akorn, Lake Forest, IL, USA) and the NO donor sodium nitroprusside (SNP; Hospira, Lake Forest, IL, USA) were chosen as control vasodilatators based on previous studies demonstrating preserved α-adrenergic responsiveness during intra-arterial infusion of these agents relative to that observed during exercise and ATP infusions (Tschakovsky et al. 2002; Rosenmeier et al. 2003b; Kirby et al. 2008; Hearon et al. 2016) Figure 1 . Experimental protocol A, after catheterization (cath) of the brachial artery and subject instrumentation, vasoconstrictor responses to the α 1 -adrenoceptor agonist phenylephrine (PE) were assessed during infusion of ATP, and during sodium nitroprusside (SNP) or adenosine (ADO) as high flow control conditions. In Protocol 1, PE responses were assessed before and after independent blockade of inwardly rectifying potassium (K IR ) channels via infusion of barium chloride (BaCl 2 ). In Protocol 2, PE responses were assessed before and after blockade of nitric oxide (NO; via L-NMMA) and prostaglandins (PGs; via ketorolac), and after combined blockade of NO, PGs, K IR channels and the sodium-potassium ATPase (ouabain). B, after baseline measurements, the vasodilatator was infused and forearm blood flow was allowed to reach a steady state. After 4 min, PE responses were assessed in the final 2 min of vasodilatator infusion and quantified as a percentage decrease in forearm vascular conductance (FVC).
et al. 2012, 2013, 2014) . N G -Monomethyl-L-arginine (L-NMMA; Bachem, Weil am Rhein, Germany) and ketorolac (Hospira) were co-administered to inhibit NO synthase and cyclooxygenase-mediated production of NO and PGs, respectively. Loading doses of L-NMMA and ketorolac were 25 mg (5 mg min −1 for 5 min) and 6 mg (600 μg min −1 for 10 min), respectively. Subsequent trials were performed during infusion of L-NMMA and ketorolac at maintenance doses of 1.25 mg min −1 and 150 μg min −1 , respectively (Dietz et al. 1994; Crecelius et al. 2010) .
General experimental protocol
Figure 1 presents the general experimental timelines (A) and the outline for each individual trial (B). Protocols 1 and 2 were performed independently in separate cohorts. The total length of each trial was 8 min, consisting of 2 min of baseline haemodynamics and 6 min of vasodilatator infusion. Infusion of the vasodilatators resulted in steady-state blood flow within 3 min, and haemodynamic measures were made between minutes 3 and 4 of vasodilatator infusion. Once steady-state blood flow was achieved, the dose of PE was infused for the final 2 min of the trial, and was calculated based on FAV and FBF to ensure consistent arterial concentrations across trials (Kirby et al. 2008 . Haemodynamic measures were repeated during the final 30 s of PE infusion.
Protocol 1: independent blockade of K IR channels (n = 7)
Given the independent contribution of K IR channels to ATP-mediated vasodilatation in humans , we first tested the effect of K IR channel blockade alone on the ability of ATP to blunt PE-mediated vasoconstriction (n = 7; 5 men, 2 women). The vasoconstrictor response to PE was assessed during infusion of ATP, and during infusion of SNP and ADO to serve as flow-matched control conditions. The order of vasodilatator infusions was counterbalanced between subjects under control conditions. Following the initial control trials, barium chloride (BaCl 2 , K IR channel inhibitor) was administered, and PE-mediated vasoconstriction was assessed during the three vasodilatator conditions in the same order they were performed prior to blockade. During control conditions the average dose of ADO and SNP used to match ATP-mediated vasodilatation was 47.2 ± 5.0 and 1.73 ± 0.4 μg (dl FAV) −1 min −1 , respectively. During BaCl 2 conditions, the average dose of ADO and SNP was 28.9 ± 5.8 and 1.53 ± 0.3 μg (dl FAV)
Protocol 2: combined blockade of NO, PGs, K IR channels and Na
Our laboratory has previously shown that NO and PGs contribute modestly to ATP-mediated vasodilatation in human forearm vasculature . Additionally, during handgrip exercise NO and PGs may interact with K IR and Na + /K + -ATPase in a compensatory manner (Crecelius et al. 2014) . Thus, we investigated the effect of NO and PG blockade alone, and in combination with blockade of K IR and Na + /K + -ATPase activity, on the ability of ATP to blunt PE-mediated vasoconstriction (n = 6; 2 men, 4 women). In this protocol, we chose to administer L-NMMA and ketorolac prior to BaCl 2 and ouabain to assess the independent effect of blocking NO and PGs alone, followed by the addition of blocking pathways related to hyperpolarization. In this way, we identify the effects of blocking autacoid production alone, vascular hyperpolarization via KIR channels alone (protocol 1) and the combined effects of the inhibitors. Due to time constraints, SNP control trials were omitted and ADO was used as the control vasodilatator. The vasoconstrictor response to PE was assessed during ATP and ADO infusion under control conditions, after administration of L-NMMA and ketorolac, and following administration of L-NMMA, ketorolac, BaCl 2 and ouabain to achieve combined inhibition of NO, PGs, K IR channels and Na + /K + -ATPase activity, respectively. The order of ATP and ADO infusion was counterbalanced between subjects under control conditions, and repeated in the same order during the blockade. The average doses of ADO used to match ATP-mediated vasodilatation during control, NO and PG blockade, and combined NO, PG, K IR channel and Na + /K + -ATPase blockade were 64.9 ± 7.2, 46.3 ± 7.1 and 62.1 ± 8.5 μg (dl FAV) −1 min −1 , respectively.
Data acquisition and analysis
Data were collected and stored on computer at 250 Hz and analysed off-line with signal-processing software (WinDaq, DATAQ Instruments, Akron, OH, USA). Baseline FBF, HR and MAP represent an average of the last 30 s of the resting time period, the steady-state hyperaemia (Pre PE; prior to PE infusion), and the effects of the α 1 -agonist (PE; after 2 min of PE infusion). We calculated the percentage reduction in FVC as our standard index to compare vasoconstrictor responses across conditions, as this appears to be the most appropriate comparison of vasoconstrictor responsiveness under conditions where there are differences in vascular tone (Lautt, 1989; O'Leary, 1991; Hearon et al. 2016 Heart rate (beats min −1 )
Control
Baseline SNP 30 ± 2 9 4 ± 2 3 2 ± 2 5 9 ± 4 ADO 28 ± 2 9 7 ± 3 3 0 ± 2 5 9 ± 4 ATP 28 ± 2 9 4 ± 2 3 0 ± 3 5 7 ± 3 Pre-PE SNP 180 ± 18 88 ± 3 204 ± 21 61 ± 4 ADO 202 ± 27 96 ± 3 209 ± 25 59 ± 4 ATP 208 ± 27 93 ± 3 223 ± 27 59 ± 3 PE SNP 71
Baseline SNP 26 ± 3 9 6 ± 4 2 8 ± 4 6 2 ± 5 ADO 34 ± 8 9 3 ± 2 3 6 ± 8 6 0 ± 5 ATP 30 ± 4 9 5 ± 2 3 1 ± 5 5 8 comprehensive, we have also presented absolute values of forearm haemodynamics for all conditions in tabular form (Tables 1 and 2 ).
Statistics
All values are reported as means ± SEM. Given the complexity of our experimental design, many comparisons are possible. We have used a statistical approach that focuses on the comparisons that are most relevant to our experimental questions. Our primary interest was the effect of blockade on vasoconstrictor responsiveness to PE within each vasodilatator condition. Vasoconstrictor responses to PE (% FVC) were compared with a two-way [trial (ATP, SNP or ADO) × condition (control and BaCl, or control, L-NMMA + ketorolac, L-NMMA + ketorolac + BaCl 2 + ouabain)] repeated-measures (RM) ANOVA. Due to the predictably large change in FBF and FVC from rest to Pre-PE (steady-state) conditions in response to ATP, SNP or ADO infusion, resting forearm haemodynamics were analysed separately by two-way (trial × condition) RM ANOVA. Absolute forearm haemodynamics were assessed by two-way [condition × time point (pre-PE or PE)] RM ANOVA inclusive of ATP, SNP and ADO trials. Systemic haemodynamics (MAP and HR) were evaluated by two-way (time point × condition) RM ANOVA. The effect of blockade on ATP vasodilatation prior to PE (Pre-PE) was assessed using one-way RM ANOVA. Student-Newman-Keuls post hoc testing was performed to make pairwise comparisons with significance set at P < 0.05.
Results
Systemic haemodynamics
Systemic haemodynamics in all experimental conditions for each protocol are presented in Tables 1 and 2 . Small changes in MAP occurred throughout the course of the experiment.
Protocol 1: independent blockade of K IR channels
As intended by experimental design, FBF and FVC during infusion of SNP and ADO were matched to levels observed during ATP infusion in all experimental conditions prior to infusion of PE (Pre-PE; Fig. 2A ). During SNP and ADO trials, direct stimulation of α 1 -adrenoceptors via infusion of PE induced robust vasoconstriction ( FVC: −59 ± 6 and −38 ± 6%, respectively) that was significantly attenuated by ATP ( FVC: −16 ± 2%, P < 0.05 vs. SNP and ADO; Fig. 2B and C) . Infusion of BaCl 2 to inhibit K IR channels had no significant effect on resting haemodynamics, but significantly attenuated the vasodilatatory response to ATP ß35% (steady-state FVC: Control: 223 ± 27, BaCl 2 : 156 ± 19 ml min −1 Heart rate (beats min −1 )
Control
Baseline ADO 32 ± 13 95 ± 3 3 3 ± 13 60 ± 2 ATP 26 ± 7 9 6 ± 3 2 7 ± 7 5 9 ± 2 Pre-PE ADO 100 mmHg −1 ; P < 0.05). After blockade, vasoconstrictor responses to PE were maintained during SNP infusion ( FVC: −60 ± 6%, P > 0.05 vs. control SNP) and significantly greater during ADO infusion ( FVC:−54 ± 5%, P < 0.05 vs. control ADO). In contrast, ATP maintained the ability to attenuate α 1 -adrenergic vasoconstriction ( FVC: −6 ± 5%, P < 0.05 vs. SNP and ADO within condition; P < 0.05 vs. control ATP, Fig. 2B and C).
As intended by experimental design, FBF and FVC during ADO infusion were matched to levels observed during ATP infusion in all experimental conditions prior to infusion of PE (Pre-PE; Fig. 3A ). During control ADO infusion, direct stimulation of α 1 -adrenoceptors via infusion of PE elicited vasoconstriction that was significantly attenuated during ATP infusion ( FVC: −42 ± 2 and −14 ± 4%, respectively; P < 0.05; Fig. 2B and C). Co-infusion of L-NMMA and ketorolac reduced resting FBF and FVC by ß25%, and also reduced steady-state FVC during ATP infusion (FVC: Control: 223 ± 60, L-NMMA + ketorolac: 160 ± 53 ml min −1 100 mmHg −1 ; P < 0.05; Fig. 3A) , consistent with effective blockade of NO and PG synthesis. Vasoconstrictor responses to PE were maintained during ADO infusion and tended to be greater than those observed in control conditions ( FVC: L-NMMA + ketorolac: −54 ± 8%; P = 0.09 vs. control; Fig. 3B and C) . Vasoconstrictor responses to PE during ATP infusion were similar to control conditions and remained significantly attenuated relative to that observed during ADO ( FVC: −14 ± 9 %; P < 0.05). Finally, combined inhibition of NO, PGs, K IR channels and Na + /K + -ATPase activity further attenuated ATP-mediated vasodilatation by ß60% (steady-state FVC: 114 ± 49 ml min −1 100 mmHg −1 ; P < 0.05 vs. ATP control). Vasoconstrictor responses to PE tended to be even greater during ADO infusion after combined inhibition of NO, PGs, K IR channels and Na + /K + -ATPase activity ( FVC: −60 ± 10%; P = 0.07 vs. Control ADO). In stark contrast, infusion of ATP maintained the ability to attenuate PE-mediated vasoconstriction ( FVC: −4 ± 14%, P < 0.05 vs. ADO within condition) ( Fig. 3B  and C) .
Discussion
The primary novel findings from the present investigation are as follows. First, the ability of intravascular ATP to attenuate α 1 -adrenergic vasoconstriction is independent of K IR channel activation in humans. Second, intravascular 
ATP-mediated sympatholysis is independent of inwardly rectifying potassium (K IR ) channels (n = 7)
A, forearm vascular conductance (FVC) at baseline, steady-state hyperaemia prior to infusion of phenylephrine (PE; Pre-PE), and at the end of 2 min of PE infusion (PE), before and after blockade of K IR channels via infusion of barium chloride (BaCl 2 ). BaCl 2 significantly reduced ATP-mediated vasodilatation by ß35%. B, individual vasoconstrictor responses to PE before and after blockade of K IR channels. C, ATP significantly attenuated PE-mediated vasoconstriction in control conditions compared with that observed during SNP and ADO. After blockade of K IR channels, despite a significant reduction in the vasodilatatory response to ATP, the ability of ATP to attenuate PE-mediated vasoconstriction remained intact. * P < 0.05 vs. Pre-PE; † P < 0.05 vs. time point in control condition; ‡ P < 0.05 vs. SNP within condition; # P < 0.05 vs. ADO within condition. . ATP-mediated sympatholysis is independent of nitric oxide, prostaglandins inwardly rectifying potassium channel and Na + /K + -ATPase activity (n = 6) A, forearm vascular conductance (FVC) at baseline, steady-state hyperaemia prior to infusion of phenylephrine (PE; Pre-PE), and at the end of 2 min of PE infusion (PE), before and after blockade of nitric oxide (NO) and prostaglandins (PGs; L-NMMA and ketorolac, respectively), and combined blockade of NO (L-NMMA), PGs (ketorolac), inwardly rectifying potassium (K IR ) channels (BaCl 2 ) and Na + /K + -ATPase (ouabain ATP maintains the ability to blunt vasoconstriction despite a 60% reduction in the vasodilatatory response during combined NO, PG, K IR channel and Na + /K + -ATPase inhibition. Given our findings using SNP and ADO as control vasodilatators, these observations clearly distinguish vasodilatation per se from the ability to modulate α-adrenergic vasoconstriction and highlight the unique nature of ATP signalling in the skeletal muscle vasculature of humans. Finally, these data are in agreement with recent findings in contracting human skeletal muscle, and suggest that vascular signalling pathways beyond NO, PGs, K IR channels and Na + /K + -ATPase are critical for both metabolic and pharmacological modulation of α-adrenergic vasoconstriction in humans (Crecelius et al. 2015b; Hearon et al. 2016) .
Exercise, intravascular ATP and vascular control
Data derived from experimental studies using a variety of approaches in both animals and humans have clearly demonstrated a unique ability of contracting muscle to blunt sympathetic vasoconstriction (i.e. functional sympatholysis), a phenomenon believed to optimize blood flow and oxygen delivery to active muscle when the sympathetic nervous system is engaged (Remensnyder et al. 1962; Joyner & Thomas, 2003; VanTeeffelen & Segal, 2003) . Many investigations have attempted to identify the substances responsible for sympatholysis (Tschakovsky et al. 2002; Rosenmeier et al. 2003b Rosenmeier et al. , 2008 Hearon et al. 2016) , although, to date, the only exogenous vasodilatator known to attenuate sympathetic vasoconstriction in quiescent muscle similar to what is observed during exercise is ATP (Rosenmeier et al. 2004 (Rosenmeier et al. , 2008 Kirby et al. 2008) . Accumulating evidence suggests that intravascular ATP may contribute to exercise hyperaemia via direct vasodilatation and by modulating sympathetic vasoconstriction, and thus there has been considerable interest in understanding the mechanisms underlying ATP signalling in the vasculature (Crecelius et al. , 2015a .
Studies in animal models demonstrate that intravascular ATP elicits a conducted vasodilatation that is dependent upon elevations in endothelial cell calcium, activation of small-and intermediate-conductance Ca 2+ -activated potassium channels (SK Ca and IK Ca , respectively), and subsequent hyperpolarization of the endothelium (Duza & Sarelius, 2003; Winter & Dora, 2007; Dietrich et al. 2009 ). Endothelium-dependent hyperpolarization (EDH) serves as the initiating electrical signal that is transduced, either directly through gap junctions, or by elevations in interstitial K + , into vasodilatation by subsequent activation of K IR channels and Na + /K + -ATPase located on vascular smooth muscle cells (Edwards et al. 1998) . In support of these findings, our laboratory recently identified a primary role (ß50%; range: 40-70%) for K IR channel activation in mediating the vasodilatatory response to intraluminal ATP in humans . Similar to ATP, the vasodilatatory response to handgrip exercise also relies on activation of K IR channels (ß30%) (Crecelius et al. 2015b) . However, blockade of K IR channels does not reduce the ability of contracting skeletal muscle to attenuate α-adrenergic vasoconstriction (Crecelius et al. 2015b ). This finding seemingly dissociates activation of K IR channels, an essential component of ATP-mediated vasodilatation, and the ability to attenuate α-adrenergic vasoconstriction. However, it is important to recognize that the local milieu of contracting skeletal muscle, and the myriad of potential vasodilatatory and/or sympatholytic stimuli, is quite complex as compared with the sole infusion of ATP. Therefore, in Protocol 1 we sought to determine whether the ability of intravascular ATP to blunt α 1 -adrenergic vasoconstriction is dependent upon K IR channel activity in humans.
Independent blockade of K IR channels and ATP-mediated sympatholysis
Given the independent role for K IR channel activation in ATP-mediated vasodilatation, we aimed to determine if K IR channel activation is required for ATP-mediated sympatholysis (Protocol 1). The present findings support previous work showing a significant contribution of K IR channels to ATP-mediated vasodilatation. In a previous study from our laboratory utilizing the same dose of ATP, we demonstrated that blockade of K IR channels and Na + /K + -ATPase reduced ATP-mediated vasodilatation by ß40%, which is line with the ß35% reduction in FVC observed in this study (Fig. 1A) . Despite the ability of K IR channel inhibition to reduce vasodilatation, α 1 -adrenergic-mediated vasoconstriction during ATP infusion was similar before and after blockade of K IR channels and remained substantially blunted relative to both ADO and SNP conditions (Fig. 2B  and C) . Thus, although K IR channel activation is a critical component of the vasodilatatory response to ATP, activation of these channels is not obligatory for intravascular ATP to attenuate α-adrenergic vasoconstriction in humans.
An interesting observation in Protocol 1 was that α 1 -adrenergic vasoconstriction was attenuated during ADO infusion relative to that observed during SNP in control conditions, and was significantly augmented following blockade of K IR channels (Fig. 2B and  C) . It is possible that under control conditions ADO-mediated vasodilatation is relatively more resistant to α 1 -adrenergic vasoconstriction than vasodilatation induced by exogenous NO administration (Rosenmeier et al. 2003b ). Similar to ATP, adenosine has been shown to elicit conducted vasodilatatory responses (Rivers et al. 2001; , although the nature of the conducted response to ADO is distinct from that observed in response to ATP. Specifically, ADO relies primarily on activation of ATP-sensitive K + (K ATP ) channels and subsequent hyperpolarization of smooth muscle (Kleppisch & Nelson, 1995; Hein & Kuo, 1999; , as opposed to ATP which relies on SK Ca /IK Ca channel activation and EDH (Winter & Dora, 2007; Dora, 2016) . To date, relatively few studies have investigated the ability of K ATP channels to modulate sympathetic vasoconstriction. In a rat hind limb preparation, pharmacological activation of K ATP channels attenuated sympathetic vasoconstriction at rest, and inhibition of K ATP channels augmented sympathetic vasoconstriction during muscle contractions (Thomas et al. 1997) . In humans, systemic administration of the K ATP channel antagonist glyburide augmented baroreflex-mediated vasoconstriction in the leg at rest, similar to animal models, whereas the exercise-induced attenuation of sympathetic vasoconstriction remained relatively intact (Keller et al. 2004) . The possibility remains that ADO modulates adrenergic vasoconstriction to some extent in resting tissues via activation of K ATP channels, although the ability of ADO to modulate α-adrenergic vasoconstriction is clearly much less potent than either ATP (Figs 2 and 3) or exercise (Tschakovsky et al. 2002; Kirby et al. 2008) .
Similar to previous studies, the PE-mediated vasoconstrictor response during ADO infusion was augmented after blockade of K IR channels (Crecelius et al. 2015b) , so it could be interpreted that K IR channel activation is in part responsible for limiting vasoconstriction during control ADO conditions. However, it is important to clarify that these studies were not designed to test this hypothesis. Specifically, the dose of ADO was adjusted in each condition to match the blunted vasodilatatory response to ATP (ADO dose: Control: 47 ± 5 μg (min) −1 , BaCl 2 : 29 ± 6 μg (min) −1 ; P = 0.07). Therefore, it is unclear whether the augmented vasoconstrictor response was due to a lower overall dose of ADO or an interaction between BaCl 2 and PE. Despite the potentially greater vasoconstrictor stimulus, there was not a similar effect of K IR channel inhibition on PE responses during SNP or ATP infusion. Additionally, recent findings from our laboratory demonstrate that activation of K IR channels, via intra-arterial infusion of KCl, fails to blunt α 1 -adrenergic vasoconstriction in humans, and may even augment vasoconstrictor responses (Hearon et al. 2016) .
Collectively, these investigations demonstrate that similar to exercise, the ability of ATP to blunt sympathetic vasoconstriction greatly exceeds that of ADO and SNP under control conditions and that while activation of K IR channels may be an important contributor to the vasodilatation observed during ATP infusion, it does not contribute to the observed attenuation of adrenergic vasoconstriction.
Blockade of NO, PGs, K IR channels and Na + /K + -ATPase and ATP-mediated sympatholysis
In addition to K IR channel activation, previous studies in humans have demonstrated a modest and variable contribution of NO and PGs to ATP-mediated vasodilatation (Rongen et al. 1994; van Ginneken et al. 2004; Mortensen et al. 2009; Crecelius et al. 2011) . One study in humans identified a potential role for NO in mediating functional sympatholysis (Chavoshan et al. 2002) , although the majority of studies employing either pharmacological inhibition of NO synthase,or direct NO donation (e.g. via infusion of SNP) suggest little independent involvement of NO in modulating sympathetic vasoconstriction at rest or during exercise in humans (Tschakovsky et al. 2002; Dinenno & Joyner, 2003; Rosenmeier et al. 2003b; Crecelius et al. 2015b; Hearon et al. 2016) . Similarly, PGs do not appear to be sympatholytic in humans . The lack of an independent effect of NO or PG inhibition could be due in part to significant interplay between NO and PG signalling Schrage et al. 2004; Markwald et al. 2011) . This idea is supported by studies showing that combined, but not independent, blockade of NO and PGs elevate vasoconstrictor responsiveness to α-adrenergic agonists in resting tissues . Further, studies in both animal models (Bauersachs et al. 1996; Sheng & Braun, 2007; Sheng et al. 2009 ) and humans (Taddei et al. 1999; de Kreutzenberg et al. 2003) indicate significant crosstalk between NO, PGs and vascular hyperpolarization. Therefore, in Protocol 2 we determined the effect of NO and PG inhibition alone, as well as combined NO, PG, K IR channel and Na + /K + -ATPase inhibition, on the ability of ATP to blunt α 1 -adrenergic vasoconstriction, similar to previous studies investigating functional sympatholysis in contracting human skeletal muscle (Crecelius et al. 2015b) .
The effect of progressive blockade is consistent with findings from previous studies . Inhibition of NO and PG production reduced ATP-mediated vasodilatation by ß20%, while addition of K IR channels and Na + /K + -ATPase further reduced vasodilatation by an additional ß40%. In total, the combined blockade reduced ATP-mediated vasodilatation by ß60%, indicating a robust and effective pharmacological blockade. During ADO infusions, the vasoconstrictor response to PE tended to be elevated after blockade of NO and PGs, and after combined blockade of NO, PG, K IR channels, and Na + /K + -ATPase activity, as observed previously in resting tissues (i.e. non-contracting skeletal muscle) Crecelius et al. 2015b) . During combined blockade of NO, PGs, K IR channels and Na + /K + -ATPase activity, all subjects except one demonstrated greater than 40% vasoconstriction in response to to −89%; Fig. 3B ), in many cases nearly abolishing the entire vasodilatatory response to ADO (Fig. 3A) . However, α 1 -adrenergic vasoconstrictor responsiveness during ATP infusion remained significantly attenuated in all subjects relative to ADO (Fig. 3B and C) , despite the significant reduction in vasodilatation. In contrast to ADO, no single subject demonstrated greater than 40% vasoconstriction to PE during combined blockade of NO, PGs, K IR channels, and Na + /K + -ATPase activity. Two subjects demonstrated a very mild vasodilatatory response during PE infusion, but in both of these subjects vasoconstriction was observed during ADO (Fig. 3B) , further highlighting the differences in how ADO and ATP interact with α 1 -adrenergic vasoconstriction. The mild vasodilatation in these subjects could be due to an unmasking of β-adrenergic vasodilatation after complete inhibition of the vasoconstrictor response to PE, similar to what is seen during administration of PE after local blockade of α-adrenoceptors (Torp et al. 2001) . These collective observations during ATP infusion are in agreement with previous studies during exercise, and demonstrate that attenuation of α 1 -adrenergic vasoconstriction during metabolic and pharmacological stimuli can occur independently of NO, PG, K IR channels and Na + /K + -ATPase activity in humans. Together, these investigations lend further insight into the similarities between vascular control in contracting skeletal muscle and during exogenous ATP administration. Clearly, infusion of a single vasodilatatory substance is different from the complex interactions between multiple signalling pathways that occur in contracting skeletal muscle. However, it is notable that intra-arterial infusion of ATP continues to mimic many features of exercise hyperaemia. Perhaps most striking is that inhibition of four key signalling pathways dramatically attenuates the vasodilatatory response to both exercise (−40%, Crecelius et al. 2015b) and ATP infusion (−60%), and that despite this, the ability of both conditions to blunt sympathetic vasoconstriction remains fully intact. These findings are also in line with previous studies that dissociate the magnitude of vasodilatatory signalling per se from the ability to attenuate sympathetic vasoconstriction and further demonstrate that even very low levels of endothelium-dependent signalling can have a profound effect on α 1 -adrenergic vasoconstriction in humans (Tschakovsky et al. 2002; Hearon et al. 2016) .
Potential mechanisms
While the specific mechanisms responsible for ATP-mediated sympatholysis remain unclear, it is clear that there are fundamental differences in the signalling mechanisms elicited by ATP that distinguish it from SNP and ADO (and other vasodilatatory substances) (Rosenmeier et al. 2008; Hearon et al. 2016) .
Perhaps most notably is the reliance of intravascular ATP on endothelium-dependent signalling to elicit vasodilatation as opposed to SNP and ADO, which elicit vasodilatation that is less reliant or independent of the endothelium (Prentice et al. 1997; Tabrizchi & Bedi, 2001; . We propose that specific signalling within the endothelium is responsible for modulating sympathetic vasoconstriction. Specifically, the primary mechanism of action for intraluminal ATP is through the activation of G q/11 protein-coupled receptors (P 2y -receptors) and subsequent EDH via activation of SK Ca and IK Ca channels (Winter & Dora, 2007) . EDH can evoke a conducted vasomotor response resulting in vasodilatation and opposition of sympathetically mediated vascular depolarization (Kurjiaka & Segal, 1995) . The ability of ATP to elicit a conducted vasodilatatory response is dependent upon activation of SK Ca and IK Ca channels (Winter & Dora, 2007) , and specific localization of IK Ca channels to myoendothelial gap junctions places them in a unique position to modulate smooth muscle cell contractility (Sandow et al. 2009 ). Indeed, IK Ca channel activity has been identified as a critical component of myoendothelial feedback whereby endothelium-dependent signalling through gap junctions limits α-adrenergic vasoconstriction (Dora et al. 2000 (Dora et al. , 2003 Tran et al. 2012) . Similar to ATP, animal models have shown that K Ca channel activation and conducted vasodilatation is a critical part of the vasodilatatory response to muscle contractions (Segal & Jacobs, 2001; Milkau et al. 2010) . Furthermore, in humans, our laboratory recently demonstrated that small increases in endothelium-dependent signalling via infusion of ATP or acetylcholine during mild intensity muscle contractions significantly increases the ability of contracting skeletal muscle to attenuate sympathetic vasoconstriction (Hearon et al. 2016) . Current pharmacology to address these exact mechanisms in humans is limited, although the prevailing evidence suggests strongly that the endothelium may be the critical site for the integration of vasodilatatory and vasoconstrictor signals, particularly in contracting skeletal muscle, and that EDH may underlie functional sympatholysis in humans (Hearon et al. 2016) .
Experimental limitations and considerations
Functional sympatholysis occurs post-junctionally at the level of the α-adrenoceptors, and involves specific signalling within the skeletal muscle vasculature. To directly investigate post-junctional signalling, PE (α 1 -adrenergic agonist) was infused to simulate sympathetic vasoconstriction. In contrast to tyramine, which induces endogenous noradrenaline release, or α 2 -adrenergic agonists, which have pre-junctional effects on noradrenaline release, PE can be used to isolate post-junctional signalling in a highly controlled manner. ATP attenuates vasoconstriction induced by both α 1 -and α 2 -adrenoceptor agonists, as well as tyramine-mediated endogenous noradrenaline release (Kirby et al. 2008; Rosenmeier et al. 2008) , and thus the selective use of PE should not limit the interpretation of the data as it relates to sympatholysis.
The effectiveness of the various pharmacological antagonists utilized in this study deserves consideration given the presence of residual vasodilatation following combined blockade of NO, PGs, K IR channels and Na + /K + -ATPase. Briefly, we utilized standard doses of L-NMMA and ketorolac that have been shown previously to be effective in attenuating NO and PG production in humans, and observed effects on haemodynamics at rest, and during vasodilatator administration Markwald et al. 2011) . Blockade of NO and PGs via L-NMMA and ketorolac, respectively, reduced resting FBF by ß25%, which is consistent with effective blockade of NO and PGs in resting tissue (Dinenno & Joyner, 2003) . The effect of combined NO and PG blockade on ATP-mediated vasodilatation (ß25%) was similar to (Mortensen et al. 2009; Crecelius et al. 2011) or greater than (Rongen et al. 1994; Crecelius et al. 2012 ) that observed in previous investigations. Regarding BaCl 2 and ouabain, we utilized doses that have been shown to abolish vasodilatation to increasing doses of intra-arterial KCl infusion , and the effect of BaCl 2 alone on ATP-mediated vasodilatation was similar to what we reported previously (ß35 vs. 40%) . Thus, we conclude that the residual vasodilatatory response to ATP primarily represents alternative signalling pathways independent of NO, PGs, K IR channels and Na + /K + -ATPase activity. Considering the pronounced effect of combined blockade on ATP-mediated vasodilatation, we do not believe that lack of inhibitor effectiveness can explain preserved attenuation of vasoconstrictor responsiveness during ATP infusion.
Conclusion
This series of studies confirms that ATP relies on activation of K IR channels, as well as NO and PGs, to elicit vasodilatation in humans. However, similar to exercise, these important vasodilatatory pathways are not obligatory to observe blunting of α-adrenergic vasoconstriction via intravascular ATP. Identification of the residual signalling pathways stimulated by ATP represents a key area of future investigation. Importantly, in the context of ageing (Koch et al. 2003) , diabetes (Holwerda et al. 2016) , hypertension (Vongpatanasin et al. 2011 ) and heart failure (Thomas et al. 2001) , all of which are characterized by elevated sympathetic nervous system activity coupled with endothelial dysfunction, impaired functional sympatholysis may be a primary contributor to the malperfusion of exercising skeletal muscle observed in these populations. Thus, the specific signalling mechanisms that underlie the ability of ATP to attenuate sympathetic vasoconstriction may represent a potentially important therapeutic target for the improvement of blood flow and oxygen delivery in these patient populations.
